The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication

Alan J. Gelenberg, Richard C. Shelton, Paul Crits-Christoph, Martin B. Keller, David L. Dunner, Robert M A Hirschfeld, Michael E. Thase, James M. Russell, R. Bruce Lydiard, Robert J. Gallop, Linda Todd, David J. Hellerstein, Paul J. Goodnick, Gabor I. Keitner, Stephen M. Stahl, Uriel Halbreich, Heather S. Hopkins

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo. Method: Seventeen subjects with DSM-IV-defined major depressive disorder who responded to St. John's wort extract in the acute-phase study (phase 1) were continued on double-blind treatment with the same preparation for 24 weeks. Ninety-five subjects who did not respond to either St. John's wort or placebo were treated with an antidepressant for 24 weeks. Results: During antidepressant treatment, mean scores on the Hamilton Rating Scale for Depression for phase 1 nonresponders decreased significantly (p < .0001), with no significant difference between St. John's wort nonresponders and placebo nonresponders. Of the 17 subjects continued on treatment with St. John's wort extract, 5 (29.4%) relapsed. Conclusions: The subjects who did not respond to St. John's wort extract or placebo in phase 1 were, by and large, not resistant to antidepressant treatment. This suggests that the lack of efficacy found by Shelton et al. in the acutephase study was unlikely to be the result of a high proportion of treatment-resistant subjects.

Original languageEnglish (US)
Pages (from-to)1114-1119
Number of pages6
JournalJournal of Clinical Psychiatry
Volume65
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Hypericum
Major Depressive Disorder
Placebos
Antidepressive Agents
Depression
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Gelenberg, A. J., Shelton, R. C., Crits-Christoph, P., Keller, M. B., Dunner, D. L., Hirschfeld, R. M. A., ... Hopkins, H. S. (2004). The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. Journal of Clinical Psychiatry, 65(8), 1114-1119. https://doi.org/10.4088/JCP.v65n0814

The effectiveness of St. John's wort in major depressive disorder : A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. / Gelenberg, Alan J.; Shelton, Richard C.; Crits-Christoph, Paul; Keller, Martin B.; Dunner, David L.; Hirschfeld, Robert M A; Thase, Michael E.; Russell, James M.; Lydiard, R. Bruce; Gallop, Robert J.; Todd, Linda; Hellerstein, David J.; Goodnick, Paul J.; Keitner, Gabor I.; Stahl, Stephen M.; Halbreich, Uriel; Hopkins, Heather S.

In: Journal of Clinical Psychiatry, Vol. 65, No. 8, 08.2004, p. 1114-1119.

Research output: Contribution to journalArticle

Gelenberg, AJ, Shelton, RC, Crits-Christoph, P, Keller, MB, Dunner, DL, Hirschfeld, RMA, Thase, ME, Russell, JM, Lydiard, RB, Gallop, RJ, Todd, L, Hellerstein, DJ, Goodnick, PJ, Keitner, GI, Stahl, SM, Halbreich, U & Hopkins, HS 2004, 'The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication', Journal of Clinical Psychiatry, vol. 65, no. 8, pp. 1114-1119. https://doi.org/10.4088/JCP.v65n0814
Gelenberg, Alan J. ; Shelton, Richard C. ; Crits-Christoph, Paul ; Keller, Martin B. ; Dunner, David L. ; Hirschfeld, Robert M A ; Thase, Michael E. ; Russell, James M. ; Lydiard, R. Bruce ; Gallop, Robert J. ; Todd, Linda ; Hellerstein, David J. ; Goodnick, Paul J. ; Keitner, Gabor I. ; Stahl, Stephen M. ; Halbreich, Uriel ; Hopkins, Heather S. / The effectiveness of St. John's wort in major depressive disorder : A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. 8. pp. 1114-1119.
@article{a7170cdf8cd74c519fa6d35b67198fbb,
title = "The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication",
abstract = "Background: A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo. Method: Seventeen subjects with DSM-IV-defined major depressive disorder who responded to St. John's wort extract in the acute-phase study (phase 1) were continued on double-blind treatment with the same preparation for 24 weeks. Ninety-five subjects who did not respond to either St. John's wort or placebo were treated with an antidepressant for 24 weeks. Results: During antidepressant treatment, mean scores on the Hamilton Rating Scale for Depression for phase 1 nonresponders decreased significantly (p < .0001), with no significant difference between St. John's wort nonresponders and placebo nonresponders. Of the 17 subjects continued on treatment with St. John's wort extract, 5 (29.4{\%}) relapsed. Conclusions: The subjects who did not respond to St. John's wort extract or placebo in phase 1 were, by and large, not resistant to antidepressant treatment. This suggests that the lack of efficacy found by Shelton et al. in the acutephase study was unlikely to be the result of a high proportion of treatment-resistant subjects.",
author = "Gelenberg, {Alan J.} and Shelton, {Richard C.} and Paul Crits-Christoph and Keller, {Martin B.} and Dunner, {David L.} and Hirschfeld, {Robert M A} and Thase, {Michael E.} and Russell, {James M.} and Lydiard, {R. Bruce} and Gallop, {Robert J.} and Linda Todd and Hellerstein, {David J.} and Goodnick, {Paul J.} and Keitner, {Gabor I.} and Stahl, {Stephen M.} and Uriel Halbreich and Hopkins, {Heather S.}",
year = "2004",
month = "8",
doi = "10.4088/JCP.v65n0814",
language = "English (US)",
volume = "65",
pages = "1114--1119",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - The effectiveness of St. John's wort in major depressive disorder

T2 - A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication

AU - Gelenberg, Alan J.

AU - Shelton, Richard C.

AU - Crits-Christoph, Paul

AU - Keller, Martin B.

AU - Dunner, David L.

AU - Hirschfeld, Robert M A

AU - Thase, Michael E.

AU - Russell, James M.

AU - Lydiard, R. Bruce

AU - Gallop, Robert J.

AU - Todd, Linda

AU - Hellerstein, David J.

AU - Goodnick, Paul J.

AU - Keitner, Gabor I.

AU - Stahl, Stephen M.

AU - Halbreich, Uriel

AU - Hopkins, Heather S.

PY - 2004/8

Y1 - 2004/8

N2 - Background: A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo. Method: Seventeen subjects with DSM-IV-defined major depressive disorder who responded to St. John's wort extract in the acute-phase study (phase 1) were continued on double-blind treatment with the same preparation for 24 weeks. Ninety-five subjects who did not respond to either St. John's wort or placebo were treated with an antidepressant for 24 weeks. Results: During antidepressant treatment, mean scores on the Hamilton Rating Scale for Depression for phase 1 nonresponders decreased significantly (p < .0001), with no significant difference between St. John's wort nonresponders and placebo nonresponders. Of the 17 subjects continued on treatment with St. John's wort extract, 5 (29.4%) relapsed. Conclusions: The subjects who did not respond to St. John's wort extract or placebo in phase 1 were, by and large, not resistant to antidepressant treatment. This suggests that the lack of efficacy found by Shelton et al. in the acutephase study was unlikely to be the result of a high proportion of treatment-resistant subjects.

AB - Background: A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo. Method: Seventeen subjects with DSM-IV-defined major depressive disorder who responded to St. John's wort extract in the acute-phase study (phase 1) were continued on double-blind treatment with the same preparation for 24 weeks. Ninety-five subjects who did not respond to either St. John's wort or placebo were treated with an antidepressant for 24 weeks. Results: During antidepressant treatment, mean scores on the Hamilton Rating Scale for Depression for phase 1 nonresponders decreased significantly (p < .0001), with no significant difference between St. John's wort nonresponders and placebo nonresponders. Of the 17 subjects continued on treatment with St. John's wort extract, 5 (29.4%) relapsed. Conclusions: The subjects who did not respond to St. John's wort extract or placebo in phase 1 were, by and large, not resistant to antidepressant treatment. This suggests that the lack of efficacy found by Shelton et al. in the acutephase study was unlikely to be the result of a high proportion of treatment-resistant subjects.

UR - http://www.scopus.com/inward/record.url?scp=4544237768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544237768&partnerID=8YFLogxK

U2 - 10.4088/JCP.v65n0814

DO - 10.4088/JCP.v65n0814

M3 - Article

C2 - 15323598

AN - SCOPUS:4544237768

VL - 65

SP - 1114

EP - 1119

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -